Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 107671, 8 pages
http://dx.doi.org/10.1155/2014/107671
Research Article

Emodin Augments Cisplatin Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells via ROS-Dependent MRP1 Downregulation

1Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
2Department of Cell Biology, Key Laboratory of the Education Ministry for Cell Differentiation and Apoptosis, Institute of Medical Sciences, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China
3Department of Medicine and UC San Diego Moores Cancer Center, University of California, La Jolla, San Diego, CA 92093, USA

Received 8 June 2014; Revised 17 September 2014; Accepted 18 September 2014; Published 14 December 2014

Academic Editor: Zhenfeng Duan

Copyright © 2014 Jun Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Agarwal and S. B. Kaye, “Ovarian cancer: strategies for overcoming resistance to chemotherapy,” Nature Reviews Cancer, vol. 3, no. 7, pp. 502–516, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Marchetti, C. Pisano, G. Facchini et al., “First-line treatment of advanced ovarian cancer: current research and perspectives,” Expert Review of Anticancer Therapy, vol. 10, no. 1, pp. 47–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Dinh, P. Harnett, M. J. Piccart-Gebhart, and A. Awada, “New therapies for ovarian cancer: cytotoxics and molecularly targeted agents,” Critical Reviews in Oncology/Hematology, vol. 67, no. 2, pp. 103–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. X. Lin, H.-K. Kim, and S. B. Howell, “The role of DNA mismatch repair in cisplatin mutagenicity,” Journal of Inorganic Biochemistry, vol. 77, no. 1-2, pp. 89–93, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Shang, X. Lin, G. Manorek, and S. B. Howell, “Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1,” Molecular Pharmacology, vol. 83, no. 1, pp. 85–94, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Gottesman, T. Fojo, and S. E. Bates, “Multidrug resistance in cancer: role of ATP-dependent transporters,” Nature Reviews Cancer, vol. 2, no. 1, pp. 48–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. X.-J. Liang, D.-W. Shen, S. Garfield, and M. M. Gottesman, “Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines,” Cancer Research, vol. 63, no. 18, pp. 5909–5916, 2003. View at Google Scholar · View at Scopus
  9. T. Iida, H. Kijima, Y. Urata et al., “Hammerhead ribozyme against γ-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins,” Cancer Gene Therapy, vol. 8, no. 10, pp. 803–814, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. G. L. Beretta, V. Benedetti, G. Cossa et al., “Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin,” Biochemical Pharmacology, vol. 79, no. 8, pp. 1108–1117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Pelicano, D. Carney, and P. Huang, “ROS stress in cancer cells and therapeutic implications,” Drug Resistance Updates, vol. 7, no. 2, pp. 97–110, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Cai, X. Niu, Y. Chen et al., “Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis,” Neoplasia, vol. 10, no. 1, pp. 41–51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Yi, J. Yang, R. He et al., “Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling,” Cancer Research, vol. 64, no. 1, pp. 108–116, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Wang, Y.-P. Sun, X.-Z. Huang et al., “Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation,” Biochemical Pharmacology, vol. 79, no. 8, pp. 1134–1140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Zhou, H. Chen, and Q. Yang, “Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance,” Zhonghua Yi Xue Za Zhi, vol. 76, no. 9, pp. 680–683, 1996. View at Google Scholar · View at Scopus
  16. K. Sinha, J. Das, P. B. Pal, and P. C. Sil, “Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis,” Archives of Toxicology, vol. 87, no. 7, pp. 1157–1180, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Berndtsson, M. Hägg, T. Panaretakis, A. M. Havelka, M. C. Shoshan, and S. Linder, “Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA,” International Journal of Cancer, vol. 120, no. 1, pp. 175–180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. Y.-I. Yang, J.-H. Kim, K.-T. Lee, and J.-H. Choi, “Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species,” Gynecologic Oncology, vol. 123, no. 3, pp. 588–596, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. X.-Z. Huang, J. Wang, C. Huang et al., “Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1,” Cancer Biology and Therapy, vol. 7, no. 3, pp. 468–475, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Kamei, T. Koide, T. Kojima, Y. Hashimoto, and M. Hasegawa, “Inhibition of cell growth in culture by quinones,” Cancer Biotherapy and Radiopharmaceuticals, vol. 13, no. 3, pp. 185–188, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. M. M. Shi, A. Kugelman, T. Iwamoto, L. Tian, and H. J. Forman, “Quinone-induced oxidative stress elevates glutathione and induces gamma-glutamylcysteine synthetase activity in rat lung epithelial L2 cells,” The Journal of Biological Chemistry, vol. 269, no. 42, pp. 26512–26517, 1994. View at Google Scholar · View at Scopus
  22. T. M. Buttke and P. A. Sandstrom, “Oxidative stress as a mediator of apoptosis,” Immunology Today, vol. 15, no. 1, pp. 7–10, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Singh, A. R. Khan, and A. K. Gupta, “Role of glutathione in cancer pathophysiology and therapeutic interventions,” Journal of Experimental Therapeutics and Oncology, vol. 9, no. 4, pp. 303–316, 2012. View at Google Scholar · View at Scopus
  24. T. Ishikawa and F. Ali-Osman, “Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells: molecular characterization of glutathione-platinum complex and its biological significance,” The Journal of Biological Chemistry, vol. 268, no. 27, pp. 20116–20125, 1993. View at Google Scholar · View at Scopus
  25. P. Borst, R. Evers, M. Kool, and J. Wijnholds, “A family of drug transporters: the multidrug resistance-associated proteins,” Journal of the National Cancer Institute, vol. 92, no. 16, pp. 1295–1302, 2000. View at Publisher · View at Google Scholar · View at Scopus